EIF5A2 and pancreatic ductal adenocarcinoma: It was recently reported that inhibiting EIF5A2 enhances the chemosensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine 40, non-small cell lung cancer (NSCLC) cells to cetuximab 41, and esophageal squamous cell carcinoma cells to 5-FU 42.